The Philippine Food and Drug Administration (FDA) approved on October 15 the Meningococcal Group B Vaccine of GlaxoSmithKline (GSK) Philippines, a global biopharma company.
The vaccine is for the prevention of meningococcal disease caused by the Neisseria meningitidis serogroup B in individuals aged two months or older.
Prior this FDA approval, there was no vaccine available for serogroup B.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
